🔗 Share this article

As the US undertakes historic revisions to its vaccination guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 shots during the pandemic and has focused upon alleged fatalities after Covid vaccination in her recent tenure at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Health officials were set to announce major changes to the childhood vaccination calendar in December, bringing the US with Denmark’s vaccine program, sources say – a major change that would place the US out of step with many the global community with little proof for public health gain. This reveal has been delayed until the next year.

Instead of the top vaccines chief, Høeg is scheduled to address the audience at the event. She was newly appointed interim head of the FDA’s CDER, the fifth person to lead the center this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric immunization guidelines in the US in order to be more similar to the Danish model, a nation with universal health coverage and a number of inhabitants approximately the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Questions Over Background

The appointee has no apparent track record in pharmaceutical research, oversight or leadership, which has been typical for former directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “understand regulatory frameworks and the research of medication creation”, commented a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

The drug center has an vast portfolio at the agency, the former commissioner pointed out.

“Many people just focuses on the novel medication approvals, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and all of those must be managed,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the position, which oversees in excess of 5,000 employees. “It’s a enormous administrative position, if you execute it properly,” she added.

Official Statement and Disputed Initiatives

In response to concerns about Høeg’s fitness for the role and whether this assignment represents more teamwork among agency officials on immunizations, a press secretary responded that the “concerns rely on incorrect assumptions”.

“Her resume aligns with the responsibilities of her position,” the official said, pointing to the months Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg inherits the agency head's recently launched expedited review system, a contentious rapid drug-approval program that allegedly troubled her predecessors. “How are these drugs being selected for this voucher program? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards laxer rules of most medications, aside from immunizations.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, history, Howard observe. She published a research paper using unconfirmed volunteer-provided data to determine the rate of heart inflammation following Covid vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the current federal leadership featured altering guidelines for recently developed shots and halting “optional” immunizations, she remarked after the election on a online show. At the FDA, Høeg has reportedly suggested barring young men from getting COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her conclusions and works backwards to accommodate the data in a extremely misleading, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|